MoonLake Immunotherapeutics is working with an investment bank to explore a sale and is having early-stage conversations with drugmakers interested in a potential acquisition, David Carnevali of Reuters reports, citing people familiar with the matter. The sources added that no deal is certain, notes Carnevali. Shares of MoonLake are up 11% to $55.79 following the report.
previous post
next post